Home
About EUVAS
Active Trials
Completed Trials
Meetings
Guidelines
Publications
Nomenclature
ANCA testing
Disease scoring
Histopathology
Links
Contact details
 

Last updated Nov 18, 2003

Publications

  1. Jayne D, Rasmussen N, Andrassy K et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36-44.
  2. Hagen EC, Daha MR, Hermans J et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int. 1998;53:743-753.
  3. Rasmussen N, Wiik A, Hoier-Madsen M et al. Anti-neutrophil cytoplasm antibodies 1988. Lancet. 1988;1:706-707.
  4. Hagen EC, Andrassy K, Csernok E et al. Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. J Immunol Methods. 1996;196:1-15.
  5. Bajema IM, Hagen EC, Hermans J et al. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int. 1999;56:1751-1758.
  6. Bajema IM, Hagen EC, Ferrario F et al. Renal granulomas in systemic vasculitis. EC/BCR Project for ANCA-Assay Standardization. Apr;49(4):272. Clin Nephrol. 1997;48:16-21.
  7. Bajema IM, Hagen EC, Hansen BE et al. The renal histopathology in systemic vasculitis: an international survey study of inter- and intra-observer agreement. Nephrol Dial Transplant. 1996;11:1989-1995.
  8. Vergunst CE, van Gurp E, Hagen EC et al. An index for renal outcome in ANCA-associated glomerulonephritis. Am J Kidney Dis. 2003;41:532-538.
  9. Hauer HA, Bajema IM, van Houwelingen HC et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int. 2002;62:1732-1742.
  10. Hauer HA, Bajema IM, Hagen EC et al. Long-term renal injury in ANCA-associated vasculitis: an analysis of 31 patients with follow-up biopsies. Nephrol Dial Transplant. 2002;17:587-596.
  11. Hauer HA, Bajema IM, van Houwelingen HC et al. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int. 2002;61:80-89.
  12. Hauer H, Bajema I, Hermans J et al. Histopathological analysis and correlation with renal functioning of biopsies in ANCA-associated systemic vasculitis. Clinical and Experimental Immunology. 1998;112 (Suppl 1):28.
  13. Luqmani RA, Exley AR, Kitas GD et al. Disease assessment and management of the vasculitides. Baillieres Clin Rheumatol. 1997;11:423-446.
  14. Bacon PA, Moots RJ, Exley A et al. VITAL (Vasculitis Integrated Assessment Log) assessment of vasculitis. Clin Exp Rheumatol. 1995;13:275-278.
  15. Luqmani R, Jayne D, Thorogood J et al. Vasculitis assessment for clinical trials. Clin Exp Immunol. 2000;120 (Suppl 1):70.
  16. Rasmussen N. European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. Clinical and Experimental Immunology. 1995;101 (Suppl 1):29-34.
  17. Jayne DR, Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc. 1997;72:737-747.
  18. Jayne D. Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol. 2001;13:48-55.
  19. de Groot K, Adu D, Savage C. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant. 2001;16:2018-2027.